GIOTRIF®
Overview
Product overview
GIOTRIF® is an irreversible ErbB inhibitor approved for the 1st-line treatment of patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC) with EGFR-TK mutations, and the treatment of patients with locally advanced or metastatic NSCLC of squamous histology progressing on or after platinum-based chemotherapy.
Product Key Facts
Indication
GIOTRIF is indicated for the 1st-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR-TK mutation(s)
GIOTRIF is indicated for treatment of patients with locally advanced or metastatic NSCLC of squamous histology progressing on or after platinum-based chemotherapy.
Active ingredient
Afatinib
Legal category
Prescription only medicine
Dosage
20 milligrams per tablet
30 milligrams per tablet
40 milligrams per tablet
50 milligrams per tablet
Administration form
Oral tablets
Dosage form
Film-coated tablets
Pack sizes
One box contains 28 film-coated
tablets in blisters.
References:
-
GIOTRIF® (afatinib), approved package insert. 28-Feb-2019+HA request Mar-2020. Approved 06/2020.
